Tirzepatide and pregnancy don't go together for weight loss. The Zepbound label says weight loss offers no benefit during pregnancy and may cause fetal harm, and it says to stop the drug once a pregnancy is recognized. Mounjaro, the same molecule labeled for type 2 diabetes, is worded differently: use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
What the U.S. labels don't give is a waiting period before trying to conceive. European and UK regulators use at least one month. And a pregnancy that started while the shots were still going is not, by itself, proof of harm, although human data on tirzepatide specifically are still thin.
Tirzepatide and pregnancy: what the Zepbound and Mounjaro labels say
DailyMed lists both the Zepbound label and the Mounjaro label as "Revised: 8/2026". Neither August update listed a change to the pregnancy sections, which agree on the evidence and differ on the advice.
On evidence, both say the available human data are too limited to tell whether tirzepatide raises the risk of birth defects, miscarriage or other problems for mother or baby. The caution comes from animals. Pregnant rats given tirzepatide while fetal organs were forming had smaller fetuses and more malformations at the highest dose tested, an exposure about half that of the top human dose; rabbits had smaller fetuses. Those effects came alongside the mothers eating less and losing weight, so how much carries over to people is unclear.
On advice, the two labels split by purpose:
| Zepbound (weight, sleep apnea) | Mounjaro (type 2 diabetes) | |
|---|---|---|
| During pregnancy | Stop once pregnancy is recognized | Use only if the potential benefit justifies the potential risk to the fetus |
| The reasoning | Weight loss offers no benefit in pregnancy and may cause fetal harm | Poorly controlled diabetes carries its own risks for mother and baby |
| Pregnancy registry | Named in the label | Not mentioned |
The Mounjaro wording is not a loophole. Poorly controlled blood sugar in pregnancy raises the risk of pre-eclampsia, miscarriage, birth defects and stillbirth, so for someone with diabetes the real question is what replaces tirzepatide, not only when it stops.
For scale, both labels give the general U.S. background: about 2–4% of recognized pregnancies involve a major birth defect and 15–20% end in miscarriage, with or without any medicine.
When to stop tirzepatide before pregnancy
The U.S. labels set no fixed interval. They ask patients to tell their prescriber about pregnancy plans, but neither names a number of weeks before conception.
Europe does. The EU product information for Mounjaro, on a European Medicines Agency page last updated August 18, 2026, says tirzepatide "should be discontinued at least 1 month before a planned pregnancy due to the long half-life." The UK regulator's GLP-1 guidance, last updated February 5, 2026, lists at least one month for tirzepatide and at least two months for semaglutide.
That gap comes from half-life (how long the body takes to clear half of a dose). Tirzepatide's is about five days, and a drug is usually treated as essentially gone after about five half-lives, roughly 25 days. Semaglutide's is about a week, which is why its window is longer. If you've seen "two months" attached to tirzepatide online, that figure belongs to semaglutide; semaglutide and pregnancy covers that rule, and how long tirzepatide stays in your system walks through the clearance math.
The prescriber sets the actual timing. For someone using tirzepatide for diabetes, stopping without a replacement plan can leave blood sugar uncontrolled at exactly the wrong moment.
Can you get pregnant on tirzepatide?
Yes, and sometimes more easily than expected, for two reasons.
The first is the pill. Tirzepatide slows stomach emptying, which can lower how much of an oral contraceptive gets absorbed, so the labels advise a non-oral method or an added barrier method for four weeks after starting and after each dose increase; tirzepatide and birth control covers that rule in full.
The second is ovulation. Losing weight and improving insulin sensitivity can make periods more regular in some people, especially those with polycystic ovary syndrome (PCOS), so a cycle that used to be unreliable may start working. Tirzepatide for PCOS goes through that evidence.
Tirzepatide and fertility
None of that makes tirzepatide a fertility treatment. The EU product information says its effect on human fertility is unknown. In rat fertility studies, the U.S. label reports no effect on sperm shape, mating, fertility or conception. Female rats had disrupted cycles and fewer implantation sites, which the label attributes to the drug's effect on eating and body weight.
What the human pregnancy studies show
The short version: data on the GLP-1 class are cautiously reassuring about accidental early exposure, and tirzepatide is a small slice of them.
The study most often cited, Cesta and colleagues in JAMA Internal Medicine (2024), followed infants of mothers with type 2 diabetes in four Nordic countries, the U.S. and Israel. Among 938 infants exposed to a GLP-1 drug around conception, the risk of major malformations was about the same as with insulin (adjusted relative risk 0.95). Its data ended in 2021, though, before Mounjaro's May 2022 approval, so none of those pregnancies involved tirzepatide.
Newer studies include tirzepatide but rarely separate it out. A 2026 analysis in Annals of Internal Medicine of 3,572 U.S. pregnancies compared women who kept filling a GLP-1 prescription into the first trimester with women who stopped. Pregnancy loss was 29.7% versus 27.1%, not a clear difference; the malformation estimates were too imprecise to rule a meaningful increase in or out. About 7 in 10 had last filled semaglutide or liraglutide.
As of September 23, 2026, the day this article was written, the newest pooled look at mothers' outcomes was a July 2026 meta-analysis in Obstetrics & Gynecology of eight studies covering 186,598 pregnancies. It found no statistically significant difference in gestational diabetes, preterm birth or preeclampsia with GLP-1 exposure around conception, and its authors noted that dual agonists such as tirzepatide were underrepresented. A separate multi-country tirzepatide pregnancy registry study, listed in the European regulators' study catalogue for the U.S., UK and Germany, plans its final report for 2036.
Stopping has a trade-off too
A 2025 study in JAMA matched 448 pregnancies in which a GLP-1 medicine was stopped before or early in pregnancy with 1,344 similar pregnancies without one. The exposed group gained more weight in pregnancy, 13.7 kg against 10.5 kg on average, and had higher rates of preterm delivery (17% vs 13%), gestational diabetes (20% vs 15%) and high blood pressure disorders (46% vs 36%).
It's observational, so it can't separate the drug from the underlying weight and metabolic risk. But it's a reason to plan the months after stopping, not just the date of the last dose.
If a pregnancy is found while tirzepatide is still in use, the useful facts are the date and dose of the last injection, the estimated weeks of pregnancy, why it was prescribed and whether diabetes is involved. Those belong with the prescriber and the prenatal clinician promptly, and the Zepbound label encourages enrollment in its pregnancy exposure registry.
Mounjaro and Zepbound while breastfeeding
Breastfeeding is a separate question, and the labels treat it as a weighing rather than a blanket rule. In a study both labels describe, 11 breastfeeding women received a single 5 mg dose. Tirzepatide was undetectable in 164 of 171 milk samples, and the total that did show up over 28 days was under 0.02% of the mother's dose.
What's missing is data on the baby and on milk supply, so the labels ask that the benefits of breastfeeding be weighed against the mother's need for the drug and any possible effect on the infant. That's a conversation for the prescriber and the pediatrician together.
Where compounded tirzepatide fits
Pregnancy guidance follows the molecule, not the brand name. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. There is no separate pregnancy evidence for it, so the label data above are the best available guide, and pregnancy plans and contraception are part of the intake.
A licensed provider reviews every request, and not everyone qualifies. Outside pregnancy, a licensed provider may still prescribe a compounded formulation when it is clinically appropriate; that decision is between you and your doctor.
